Becton, Dickinson and Company (BDX)
| Market Cap | 64.77B |
| Revenue (ttm) | 19.83B |
| Net Income (ttm) | 1.41B |
| Shares Out | 289.04M |
| EPS (ttm) | 4.84 |
| PE Ratio | 46.26 |
| Forward PE | 15.62 |
| Dividend | $3.80 (1.70%) |
| Ex-Dividend Date | Sep 9, 2024 |
| Volume | 1,319,329 |
| Open | 225.20 |
| Previous Close | 225.15 |
| Day's Range | 223.98 - 228.08 |
| 52-Week Range | 218.75 - 249.89 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 283.00 (+26.28%) |
| Earnings Date | Nov 7, 2024 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascula... [Read more]
Financial Performance
In 2023, BDX's revenue was $19.37 billion, an increase of 2.66% compared to the previous year's $18.87 billion. Earnings were $1.42 billion, a decrease of -15.69%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for BDX stock is "Strong Buy." The 12-month stock price forecast is $283.0, which is an increase of 26.28% from the latest price.
News
Becton, Dickinson and Company Q4: Shifting To High-Growth Areas
Becton, Dickinson and Company is projected to achieve 8.8%-9.3% revenue growth in FY25, driven by new product launches and the APM business. The acquisition of Edwards Lifesciences' Critical Care prod...
Becton, Dickinson and Company (BDX) Q4 2024 Earnings Call Transcript
Becton, Dickinson and Company (NYSE:BDX) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer & Head of Investor Relations...
Becton Dickinson beats quarterly estimates on strength in drug-delivery devices
Becton Dickinson surpassed analysts' expectations for fourth-quarter results on Thursday, helped by strong demand for its drug-delivery devices.
BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organic Q4 GAAP and adjusted diluted EPS from con...
BD Board Increases Dividend for 53rd Consecutive Year
FRANKLIN LAKES, N.J. , Nov. 7, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $1.04 per common share, an increase of...
Becton, Dickinson And HP Among 13 Companies To Announce Annual Dividend Increases In First Half Of November
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 13 companies to announce their annual increases i...
BD Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations
FRANKLIN LAKES, N.J. , Oct. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched the new BD® Intraosseous Vascular Acces...
My Best Dividend Aristocrats For November 2024
The ProShares S&P 500 Dividend Aristocrats ETF went on a great run during Q3, gaining 11.6% during the quarter. I present 3 strategies that can theoretically beat the dividend aristocrat index in the ...
BD Named Among the 100 Best Corporate Citizens of 2024
FRANKLIN LAKES, N.J. , Oct. 25, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named as one of the 100 Be...
Why These 2 Dividend Aristocrats Look Like Buys Today
Twenty-five consecutive years of dividend growth and economic moats work in these undervalued stocks' favor. 00:00 Introduction 01:02 Chevron CVX 01:37 Becton Dickinson BDX Susan Dziubinski: I'm Susan...
BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research
Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing FRANKLIN LAKES, N.J. , Oct. 14, 2024 /PRNewswire/ -- B...
BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results
Announces Dates for Fiscal 2025 Quarterly Earnings Webcasts FRANKLIN LAKES, N.J. , Oct. 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology com...
Undervalued Dividend Kings: October 2024
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for pote...
BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation
No admission of liability or wrongdoing; settlement structured to eliminate uncertainty for all stakeholders related to settled cases. Settlement amount within current product litigation reserve and w...
My Best Dividend Aristocrats For October 2024
The ProShares S&P 500 Dividend Aristocrats ETF extends it's good form in the second half of 2024, adding a gain of 3.69% in August. I present 3 strategies that can theoretically beat the dividend aris...
New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion
FRANKLIN LAKES, N.J. , Sept. 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data that highlights how its adva...
Why Matrix CIO is chasing Becton Dickinson and US Bancorp
David Katz, chief investment officer at Matrix Asset Advisors, joins 'The Exchange' to discuss his picks in the markets, how to position for the future, and more.
BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics
LE PONT-DE-CLAIX, France , Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak...
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position...
Becton, Dickinson and Company (BDX) Wells Fargo 2024 Healthcare Conference
Becton, Dickinson and Company (NYSE:BDX) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:45 AM ET Company Participants Tom Polen - Chairman, President & CEO Conference Call Participants La...
Edwards Lifesciences Completes Sale of Critical Care
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX) for $4.2 billi...
BD Completes Acquisition of Critical Care from Edwards Lifesciences
Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision tools Combination of leading monitoring and infusion plat...
BD Celebrates 75 years of U.S. Manufacturing Excellence in Nebraska
Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J. , Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical techno...
BD Names Michael Feld as President of Life Sciences Segment
FRANKLIN LAKES, N.J. , Aug. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Michael Feld has been named execu...
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the ...